P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS

P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS

Bibliographic Details
Main Authors:	S. Garciaz, M.-A. Hospital, A.-S. Alary, C. Saillard, Y. Hicheri, B. Mohty, J. Rey, E. D’incan, A. Charbonnier, V. Ferdinand, V. Maisano, L. Lombardi, A. Ittel, M.-J. Mozziconacci, V. Gelsi-Boyer, N. Vey
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845024.01860.8d

Similar Items

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
by: Sylvain Garciaz, et al.
Published: (2022-04-01)

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
by: Sylvain Garciaz, et al.
Published: (2021-11-01)

PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO-BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER.
by: Guillaume Berton, et al.
Published: (2023-08-01)

PB1810: OUTCOME OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANT: A SINGLE INSTITUTION RETROSPECTIVE STUDY
by: C. Castoldi, et al.
Published: (2022-06-01)

Venetoclax Resistance in Acute Myeloid Leukemia
by: Sylvain Garciaz, et al.
Published: (2024-03-01)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
by: Hua Jin, et al.
Published: (2023-04-01)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
by: N. Daver, et al.
Published: (2022-06-01)

P412: LOW EXPOSURE, EXTENDED DOSING MIMICKING CLINICAL EXPOSURES OF ORAL AZACITIDINE SYNERGIZES WITH VENETOCLAX IN PRECLINICAL AML MODELS
by: D. Jeyaraju, et al.
Published: (2022-06-01)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
by: Deepak Kumar Shukla, et al.
Published: (2021-01-01)

P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)
by: E. Stein, et al.
Published: (2022-06-01)

P563: A RANDOMIZED, DOUBLE-BLIND, 2-ARM, MULTICENTER, PH3 STUDY OF VENETOCLAX & ORAL AZACITIDINE VS. ORAL AZACITIDINE AS MAINTENANCE THERAPY FOR PTS WITH AML IN FIRST REMISSION AFTER INTENSIVE CHEMOTHERAPHY
by: V. Ivanov, et al.
Published: (2022-06-01)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
by: L. Minarik, et al.
Published: (2022-06-01)

RELAPSED UBTF-TD MDS TREATED WITH VENETOCLAX AND AZACITIDINE
by: Henrik Hasle, et al.
Published: (2023-12-01)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
by: Marina Konopleva, et al.
Published: (2023-08-01)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
by: Wenjian Wei, et al.
Published: (2023-08-01)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
by: Mustafa Nissar Bankur, et al.
Published: (2022-06-01)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
by: Ian M. Bouligny, et al.
Published: (2023-05-01)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
by: Nicholas J. Short, et al.
Published: (2023-07-01)

Multiple cytogenetics forms of KMT2A amplification and jumping translocation in a case of myelodysplastic syndrome
by: Antoine Ittel, et al.
Published: (2021-11-01)

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
by: N. G. Daver, et al.
Published: (2022-06-01)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
by: Yu Cui, et al.
Published: (2024-12-01)

Sweet Syndrome in a Patient with Acute Leukemia on Azacitidine and Venetoclax Treatment
by: Rezmuves Maria Gabriela, et al.
Published: (2023-09-01)

Erythroleukemia: Classification
by: Nathalie Cervera, et al.
Published: (2023-05-01)

P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: A. M. Zeidan, et al.
Published: (2022-06-01)

PB1813: EFFICACY OF AZACITIDINE AND VENETOCLAX IN AML PATIENTS MAY BE LIMITED BY INTERACTION WITH POSACONAZOLE AND LACK OF STANDARDISED TREATMENT PROTOCOL. REAL WORLD DATA FROM 3 MAJOR CENTRES IN SINGAPORE.
by: D. Christopher, et al.
Published: (2022-06-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
by: G. Garcia-Manero, et al.
Published: (2022-06-01)

AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and reduced infusion-related reactions
by: Daver, N, et al.
Published: (2022)

P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
by: J.-Z. Hou, et al.
Published: (2022-06-01)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
by: Leiming Xia, et al.
Published: (2023-05-01)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
by: Andrius Žučenka, et al.
Published: (2023-08-01)

EXPLORING THE EFFICACY OF AZACITIDINE AND VENETOCLAX COMBINATION IN TREATING ACUTE MYELOID LEUKEMIA IN CASES OF RELAPSE FOLLOWING AZACITIDINE TREATMENT AND HIGH-DOSE VITAMINS THERAPY
by: VM Sthel, et al.
Published: (2023-10-01)

Venetoclax: A Game Changer in the Treatment of Younger AML Patients?
by: Matteo Molica, et al.
Published: (2023-12-01)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
by: Ryosuke Naka, et al.
Published: (2023-08-01)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, CA, et al.
Published: (2022)

P540: PEVONEDISTAT, AZACITIDINE AND VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA– A PHASE I STUDY
by: G. S. Guru Murthy, et al.
Published: (2022-06-01)